ATLX-1088 is regarded as a possible first-in-class human antibody targeting CD33 – a cell surface protein
Category: Uncategorized
Updated Date: Wed, 14 Jun 2023 00:00:00 EDT
Updated Date: Wed, 14 Jun 2023 00:00:00 EDT
Updated Date: Wed, 14 Jun 2023 00:00:00 EDT
Updated Date: Wed, 14 Jun 2023 00:00:00 EDT
Updated Date: Wed, 14 Jun 2023 00:00:00 EDT
The BMJ Commission on the Future of the NHS should make overmedicalisation a major theme for the reasons […]
Mathew’s eloquent piece and its rapid responses prompt me to point out that there are trade-offs in risk […]
During research there were not any clinically-relevant adverse events or psychotomimetic effects